Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health care and social assistance tags : Thyroid save search
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
Published: 2023-12-18 (Crawled : 13:00) - biospace.com/
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
|
| O: 1.04%
H: 11.12%
C: 8.39%
vrdn-003 disease positive thyroid eye program therapeutics potential study
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
|
| O: 0.77%
H: 8.93%
C: 7.74%
drug device disease thyroid eye therapeutics agreement
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Published: 2022-03-21 (Crawled : 14:20) - globenewswire.com
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
|
| O: 0.75%
H: 6.59%
C: 1.34%
vrdn-002 disease antibody treatment thyroid eye trial therapeutics
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2023-01-08 (Crawled : 16:20) - globenewswire.com
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
vrdn-001 ongoing thyroid disease eye trial positive phase 1
Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
Published: 2022-12-21 (Crawled : 13:00) - biospace.com/
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
|
| O: 0.18%
H: 7.62%
C: 7.15%
thyroid disease eye trial therapeutics
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
|
| O: -2.49%
H: 6.5%
C: 1.6%
vrdn-001 ongoing thyroid disease eye trial positive phase 1
Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
Published: 2022-10-22 (Crawled : 20:20) - globenewswire.com
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
vrdn-001 ongoing thyroid disease active meeting eye trial positive
Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
Published: 2022-10-12 (Crawled : 12:20) - globenewswire.com
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
|
| O: -0.76%
H: 2.19%
C: 1.63%
thyroid meeting therapeutics
Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2022-08-15 (Crawled : 11:00) - globenewswire.com
VRDN | $14.57 1.89% 120K
|
Health Care and Social Assistan...
|
| O: 35.85%
H: 26.84%
C: 9.95%
vrdn-001 ongoing thyroid disease eye positive phase 1
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.